ViiV Healthcare's Pipeline Sharing With Generic Makers "Meaningless" In Absence Of Technology - Cipla, IPA
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Cipla - India's biggest generic drug maker and among the largest manufacturers of generic anti-retroviral drugs in the world - expressed measured optimism to ViiV Healthcare's decision on offering access to the portfolio of its present and future pipeline of anti-retroviral medicines to 69 least developed and low-income countries without any royalty charges. Even so, a Cipla spokesman said he doubted if the steps announced on improving access to the medicines can be implemented
You may also be interested in...
HIV Pricing Programs Can Help, But More Access And Innovation Needed - IFPMA
HONG KONG - Innovative and generic companies both contribute to the fight against HIV/AIDS, and while putting downward pressure on prices to improve access remains important, new novel medicines are still needed, suggests a new report on access to HIV/AIDS medicines
HIV Pricing Programs Can Help, But More Access And Innovation Needed - IFPMA
HONG KONG - Innovative and generic companies both contribute to the fight against HIV/AIDS, and while putting downward pressure on prices to improve access remains important, new novel medicines are still needed, suggests a new report on access to HIV/AIDS medicines
ViiV Offers Entire HIV/AIDS Portfolio To Generic Firms In Low-Income Countries, No Royalties Attached
With the problem of public access to medicines largely overcome, the new challenge is to get the more high-tech therapies to people with HIV/AIDS in the least developed countries, a spokeswoman said.